This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meijer-van Gelder, M. E. Articles by Foekens, J. A. Search for Related Content PubMed PubMed Citation Articles by Meijer-van Gelder, M. E. Articles by Foekens, J. A. Social Bookmarking                            What's this?

Breast-Conserving Therapy: Proteases as Risk Factors in Relation to Survival After Local Relapse

From the Division of Endocrine Oncology, Department of Medical Oncology, Rotterdam Cancer Institute, Dr. Daniel den Hoed Kliniek/Academic Hospital Rotterdam, Rotterdam, the Netherlands.

Address reprint requests to Marion E. Meijer-van Gelder, MD, Josephine Nefkens Institute, Room Be428, Dr Molewaterplein 50, 3015 GE Rotterdam, the Netherlands.

PURPOSE: To evaluate whether cathepsin D, urokinase-type plasminogen activator (uPA), its inhibitor, plasminogen activator inhibitor-1 (PAI-1), or clinical factors can predict which patients are at risk for developing distant metastases after local recurrence (LR).

PATIENTS AND METHODS: Of 1,630 patients treated with breast-conserving surgery and radiotherapy of the breast between 1980 and 1992, LR developed in 171 as a first event. From the available primary tumor tissues, we determined the cytosolic levels of cathepsin D, uPA and PAI-1.

RESULTS: In patients with LR, a short ( 2 years) disease-free interval (DFI) and skin involvement of LR were associated with poor postrelapse distant metastasis-free survival (PR-DMFS, P = .001, both) and postrelapse overall survival (PR-OS; P < .0001 and P < .0002, respectively). The primary tumor levels of uPA and PAI-1 were elevated for patients with a short DFI (P < .01), but such a relation was not observed for patients with skin involvement. In univariate analyses, high levels of uPA and PAI-1 in the primary tumor were associated with poor PR-OS (P = .038 and P = .040, respectively) but not PR-DMFS. In Cox multivariate analyses for PR-DMFS and PR-OS, only a short DFI and skin involvement of the LR were independently associated with a poor clinical outcome.

CONCLUSION: In patients treated with breast-conserving therapy who had LR as a first event, a short DFI and skin involvement were strong indicators for poor PR-DMFS and PR-OS. The proteases studied did not contribute significantly to the final multivariate model.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E A Baker, T J Stephenson, M W R Reed, and N J Brown Expression of proteinases and inhibitors in human breast cancer progression and survival Mol. Pathol., October 1, 2002; 55(5): 300 - 304. [Abstract] [Full Text] [PDF]